Hormone naive | Neo-adjuvant ADT | |||
---|---|---|---|---|
monotherapy | Combined EBRT | monotherapy | Combined EBRT | |
(n=103) | (n=38) | (n=34) | (n=17) | |
PSA elevation rate of 0.1 ng/mL or greater | 51 (50%) | 25 (66%) | 9 (27%) | 6 (35%) |
Frequency of PSA bounce | 29 (28%) | 12 (32%) | 3 (18%) | 15 (18%) |
Time to bounce (mos) | 17.4, 17, (5-36) | 14.8, 11.5 (5-35) | 13.7, 8.5, (5-26) | 18.3, 15, (14-26) |
Mean, median, (range) | ||||
Height (ng/mL) | 0.51, 0.34, (0.13-1.74) | 0.48, 0.26, (0.12-1.85) | 0.19, 0.16, (0.10-0.40) | 0.90, 0.68, (0.16-1.87) |
Mean, median, (range) | ||||
Duration (mos) | 9.1, 6.0, (3-36) | 11.8, 11.5, (2-31) | 6.0, 6.0, (3-9) | 15.3, 17.0, (7-22) |
Mean, median, (range) | ||||
3-yr bounce free rate (%) | 68.8 | 80.6 | 66.7 | 80.9 |